

Therapeutic solutions to improve the lives of Canadians



Sanofi-aventis Canada Inc. is the Canadian affiliate of the sanofi-aventis Group, one of the world's leading pharmaceutical companies.

We are headquartered in Laval, Quebec, and employ more than **900 people** across the country. Our Laval site is also home to a **world-class manufacturing facility** that produces medications for use by patients in Canada, the United States and other countries.

As a **leading health care partner** we provide, and are developing, innovative medicines in several therapeutic areas: **cardiovascular diseases, thrombosis, oncology, diabetes, the central nervous system** and **internal medicine**. At the same time, we continue to supply a range of mature products that form the basis of long-standing therapies. ■

Major products

Actonel^{®†}, Apidra[™],
Apidra[™] SoloSTAR[®], Avalide^{®*},
Avapro[®], Eligard[®], Eloxatin[®],
Lantus[®], Lantus[®] SoloSTAR[®],
Lovenox[®], Multaq[™], Plavix^{®*},
Taxotere[®], Xatral[®]

*Co-promoted with Bristol-Myers Squibb Canada Co.

† Co-promoted with Procter & Gamble Pharmaceuticals Canada, Inc. ■



Major investor in biopharmaceutical R&D

With combined R&D investments of \$211.5 million in 2008, the **sanofi-aventis Group** (sanofi-aventis and sanofi pasteur) is a leader in Canada's biopharmaceutical sector, a critical knowledge-based industry that generates jobs, business and opportunity throughout the country. ■

Clinical research expertise

Sanofi-aventis Canada has acquired particular expertise in the area of clinical studies, which evaluate the safety, efficacy, optimal dosage and potential side effects of medications. The company operates **one of the sanofi-aventis Group's largest clinical research units** and is overseeing some 110 studies in hospitals and clinics across the country. ■



Sanofi Pasteur: a leader in vaccines

Our sister company, **Sanofi Pasteur Limited**, represents the sanofi-aventis Group's vaccines division in Canada. Based in Toronto, the company employs more than 1,100 people and is **Canada's largest vaccines producer**, supplying the Canadian, U.S. and international markets. As one of its many milestones, sanofi pasteur in Canada researched and developed a five-component pertussis vaccine used to protect children and adults around the world from whooping cough. ■

Sound environmental practices

Concern for the environment runs high at the Laval site, where our employees have implemented many exemplary practices. Office supplies are reused or given to local schools; the cafeteria sends food waste for composting and uses no disposable dishes or cutlery. **The site recycles 86% of its residual materials** and has **earned the highest level of certification** from the Quebec government's *ICI on recycle!* program. ■



We support:

The Advanced Coronary Treatment (ACT) Foundation of Canada, which promotes training of high school students in cardiopulmonary resuscitation (CPR) and heart health.

The Foundation for Research into Children's Diseases, which raises funds for pediatric research in Quebec.

Health Partners International of Canada, which provides donated Canadian medicines, medical supplies and vaccines to people around the world.

PROCURE, which supports and conducts activities aimed at preventing and curing prostate cancer.

The Heart and Stroke Foundation of Canada, which provides information about heart, stroke, and healthy living.

The Colorectal Cancer Association of Canada, which supports patients and advocates for population-based screening and timely access to effective treatments.

The Canadian Diabetes Association, which supports people affected by diabetes by providing information, diabetes research, education, service and advocacy. ■

Resourceful team attracts business to Canada

The sanofi-aventis pharmaceutical plant in Laval, Quebec, is a **nimble and efficient operation** experienced at incorporating new product lines quickly and cost-effectively. Since 2000, the plant has undergone four expansions and stepped up its efforts to secure **international manufacturing mandates** from our parent company. Today, some 50% of the medications produced at the Laval facility are destined for other countries, mainly the U.S. and Australia. ■



Health care partner

Often working in **partnership with patient associations**, we fund and develop programs that help people get their high blood pressure under control, recover from strokes or heart attacks, or better manage their diabetes. We also offer one of the most comprehensive ranges of **continuing education courses for health care professionals**. Developed by leading physicians and accredited by professional orders and universities, these courses provide an essential service by helping doctors stay up-to-date with advances in treatments, clinical guidelines and research. ■

